Patents by Inventor Iain Robert THOMPSON

Iain Robert THOMPSON has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHOD FOR TREATING ALZHEIMER'S DISEASE BY TARGETING MAPT GENE
    Publication number: 20230248810
    Abstract: A polynucleotide, comprising the following base sequences: (a) a base sequence encoding a fusion protein of a nuclease-deficient CRISPR effector protein and a transcription repressor, and (b) a base sequence encoding a guide RNA targeting a continuous region of 18 to 24 nucleotides in length in a region set forth in SEQ ID NO: 54, 55, 56, 57, 68, 153 or 97 in the expression regulatory region of human MAPT gene. are expected to be useful for treating or preventing tauopathy including Alzheimer's disease.
    Type: Application
    Filed: July 9, 2021
    Publication date: August 10, 2023
    Applicant: Modalis Therapeutics Corporation
    Inventors: Iain Robert THOMPSON, Tetsuya YAMAGATA, Talha AKBULUT
  • Method of treating diseases associated with elevated KRAS expression using CRISPR-GNDM system
    Patent number: 11591621
    Abstract: The present invention provides a method of treating a disease associated with elevated KRAS activity or expression in a subject, comprising suppressing KRAS expression in the subject by targeting an expression regulatory region of KRAS gene using a CRISPR-Guide Nucleotide Directed Modulation (GNDM). Also, provided is a CRISPR-GNDM system for suppressing KRAS expression comprising (a) a protein selected from the group consisting of dCas9 or dCpf1, a fusion protein of dCas9 or dCpf1 and Kruppel associated box (KRAB), and (b) a guide nucleotide targeting an expression regulatory region of KRAS gene.
    Type: Grant
    Filed: February 7, 2018
    Date of Patent: February 28, 2023
    Assignee: Modalis Therapeutics Corporation
    Inventors: Tetsuya Yamagata, Yuanbo Qin, Haruhiko Morita, Talha Akbulut, Iain Robert Thompson
  • Method for treating muscular dystrophy by targeting utrophin gene
    Patent number: 11473071
    Abstract: Polynucleotides comprising the following base sequences: (a) a base sequence encoding a fusion protein of a nuclease-deficient CRISPR effector protein and a transcription activator, and (b) a base sequence encoding a guide RNA targeting a continuous region of 18 to 24 nucleotides in length in a region set forth in SEQ ID NO: 104, 105, 135, 141, 153, 167, or 172 in the expression regulatory region of human Utrophin gene are expected to be useful for treating or preventing DUCHENNE muscular dystrophy or BECKER muscular dystrophy.
    Type: Grant
    Filed: May 14, 2021
    Date of Patent: October 18, 2022
    Assignees: ASTELLAS PHARMA INC., MODALIS THERAPEUTICS CORPORATION
    Inventors: Eiji Yoshimi, Katsuro Yoshioka, Tetsuya Yamagata, Yuanbo Qin, Iain Robert Thompson, Nidhi Khanna
  • Method of treating diseases associated with MYD88 pathways using CRISPR-GNDM system
    Patent number: 11439692
    Abstract: The present invention provides a method of treating a disease associated with activated MYD88 signaling in a subject, including suppressing MYD88 expression in a subject by targeting an expression regulatory region of MYD88 gene by using a CRISPR-Guide Nucleotide Directed Modulation (GNDM), without affecting the expression of an adjacent ACAA1 gene. Also, provided is a CRISPR-GNDM system for suppressing MYD88, including expression comprising (a) a protein selected from the group consisting of dCas9 or dCpf1, a fusion protein of dCas9 or dCpf1 and Kruppel associated box (KRAB) and (b) a guide RNA (gRNA) targeting an expression regulatory region of MYD88 gene.
    Type: Grant
    Filed: May 17, 2018
    Date of Patent: September 13, 2022
    Assignee: Modalis Therapeutics Corporation
    Inventors: Tetsuya Yamagata, Yuanbo Qin, Iain Robert Thompson, Haruhiko Morita
  • METHOD FOR TREATING MUSCULAR DYSTROPHY BY TARGETING UTROPHIN GENE
    Publication number: 20210355464
    Abstract: Polynucleotides comprising the following base sequences: (a) a base sequence encoding a fusion protein of a nuclease-deficient CRISPR effector protein and a transcription activator, and (b) a base sequence encoding a guide RNA targeting a continuous region of 18 to 24 nucleotides in length in a region set forth in SEQ ID NO: 104, 105, 135, 141, 153, 167, or 172 in the expression regulatory region of human Utrophin gene are expected to be useful for treating or preventing DUCHENNE muscular dystrophy or BECKER muscular dystrophy.
    Type: Application
    Filed: May 14, 2021
    Publication date: November 18, 2021
    Applicants: ASTELLAS PHARMA INC., MODALIS THERAPEUTICS CORPORATION
    Inventors: Eiji YOSHIMI, Katsuro YOSHIOKA, Tetsuya YAMAGATA, Yuanbo QIN, Iain Robert THOMPSON, Nidhi KHANNA